Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1972 1
1976 1
1979 1
1982 4
1983 4
1984 6
1985 4
1986 9
1987 1
1988 5
1989 2
1990 6
1991 4
1992 8
1993 3
1994 7
1996 5
1997 2
1998 5
1999 5
2000 1
2001 5
2002 3
2003 3
2004 4
2006 2
2007 3
2008 2
2010 3
2011 6
2012 1
2013 7
2014 11
2015 8
2016 9
2017 9
2018 7
2019 4
2020 9
2021 8
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
APOE gene variants in primary dyslipidemia.
Khalil YA, Rabès JP, Boileau C, Varret M. Khalil YA, et al. Atherosclerosis. 2021 Jul;328:11-22. doi: 10.1016/j.atherosclerosis.2021.05.007. Epub 2021 May 23. Atherosclerosis. 2021. PMID: 34058468 Free article. Review.
In the presence of other risk factors, apoE2 homozygotes could develop type III hyperlipoproteinemia (familial dysbetalipoproteinemia or FD), an atherogenic disorder characterized by an accumulation of remnants of triglyceride-rich lipoproteins. ...
In the presence of other risk factors, apoE2 homozygotes could develop type III hyperlipoproteinemia (familial dysbetal …
Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.
Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Sniderman AD, et al. JAMA Cardiol. 2019 Dec 1;4(12):1287-1295. doi: 10.1001/jamacardio.2019.3780. JAMA Cardiol. 2019. PMID: 31642874 Free PMC article. Review.
The net result is, with the exceptions of the abnormal chylomicron remnants in type III hyperlipoproteinemia and lipoprotein (a), all apoB particles are equally atherogenic. ...
The net result is, with the exceptions of the abnormal chylomicron remnants in type III hyperlipoproteinemia and lipopr …
Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Falko JM. Falko JM. Endocr Pract. 2018 Aug;24(8):756-763. doi: 10.4158/EP-2018-0157. Endocr Pract. 2018. PMID: 30183397 Review.
This review provides a summary of clinical characteristics of FCS that can be potentially used to screen patients in an endocrinologist's office and direct them to the appropriate standard of care. ABBREVIATIONS: apoB = apolipoprotein B; apoC-III = apolipoprotein CIII; ASO …
This review provides a summary of clinical characteristics of FCS that can be potentially used to screen patients in an endocrinologist's of …
Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Turgeon RD, Barry AR, Pearson GJ. Turgeon RD, et al. Can Fam Physician. 2016 Jan;62(1):32-7. Can Fam Physician. 2016. PMID: 26796832 Free PMC article. Review.
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of randomized controlled trials), level II (observational study), or level III (expert opinion). The best available evidence is mostly level …
A supporting level of evidence for each recommendation was categorized as level I (randomized controlled trial or systematic review of rando …
Severe hypertriglyceridemia: Existing and emerging therapies.
Malick WA, Do R, Rosenson RS. Malick WA, et al. Pharmacol Ther. 2023 Nov;251:108544. doi: 10.1016/j.pharmthera.2023.108544. Epub 2023 Oct 15. Pharmacol Ther. 2023. PMID: 37848164 Review.
Genetic discoveries have allowed for the development of novel pathway-specific therapeutics targeting LPL modulating proteins. New targets directed towards inhibition of apolipoprotein C-III (apoC-III), angiopoietin-like protein 3 (ANGPTL3), angiopoietin-like protei …
Genetic discoveries have allowed for the development of novel pathway-specific therapeutics targeting LPL modulating proteins. New targets d …
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.
Yanai H, Adachi H, Hakoshima M, Katsuyama H. Yanai H, et al. Int J Mol Sci. 2023 Sep 11;24(18):13942. doi: 10.3390/ijms241813942. Int J Mol Sci. 2023. PMID: 37762244 Free PMC article. Review.
Postprandial hyperlipidemia is observed in patients with familial type III hyperlipoproteinemia, familial combined hyperlipidemia, chronic kidney disease, metabolic syndrome and type 2 diabetes. ...
Postprandial hyperlipidemia is observed in patients with familial type III hyperlipoproteinemia, familial combined hype …
PCSK9 inhibitors.
Farnier M. Farnier M. Curr Opin Lipidol. 2013 Jun;24(3):251-8. doi: 10.1097/MOL.0b013e3283613a3d. Curr Opin Lipidol. 2013. PMID: 23652470 Review.
SUMMARY: The short-term efficacy, safety and tolerability of two monoclonal antibodies to PSCK9 have been demonstrated in several phase II trials. These PCSK9 inhibitors are now tested in larger phase III studies to provide insights into the long-term safety and clinical e …
SUMMARY: The short-term efficacy, safety and tolerability of two monoclonal antibodies to PSCK9 have been demonstrated in several phase II t …
Lomitapide.
[No authors listed] [No authors listed] Am J Cardiovasc Drugs. 2011 Oct 1;11(5):347-52. doi: 10.2165/11533560-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21846156 Review.
Oral, once-daily lomitapide will be targeted at patients resistant to HMG-CoA reductase inhibitors (statins) either due to abnormalities in liver function or to discontinuation because of muscle pain. An oral formulation of lomitapide is in phase III development for homozy …
Oral, once-daily lomitapide will be targeted at patients resistant to HMG-CoA reductase inhibitors (statins) either due to abnormalities in …
Lipid-lowering agents.
Ewang-Emukowhate M, Wierzbicki AS. Ewang-Emukowhate M, et al. J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):401-11. doi: 10.1177/1074248413492906. Epub 2013 Jun 27. J Cardiovasc Pharmacol Ther. 2013. PMID: 23811423 Review.
It also discusses the human trial data on some novel therapeutic agents that are being developed including those for homozygous familial hypercholesterolemia--the antisense oligonucleotide mipomersen and the microsomal transfer protein inhibitor lomitapide. Data are presented on …
It also discusses the human trial data on some novel therapeutic agents that are being developed including those for homozygous familial hyp …
189 results